Dr. Reddy’s Expects Strong Q3 And Q4 Performance After Fixing Semaglutide Problems

Market snapshot: Dr. Reddy's Laboratories expects to resolve its generic semaglutide active pharmaceutical ingredient (API) quality issues by the third week of September 2026, aiming to resume commercial finished product supplies by late October or early November 2026. The temporary supply halt impacted Q1 FY27 earnings with a ₹240 crore one-time provision, contributing to a 69% year-on-year drop in net profit. However, the management is optimistic about supplying 6 million to 7 million pens during Q3 and Q4 of FY27, maintaining its double-digit revenue growth guidance.

Data Snapshot

• A provision of ₹240 crore was booked in Q1 FY27 to account for semaglutide API inventory write-downs and associated costs.
• Q1 FY27 consolidated revenue declined 5.6% year-on-year to ₹8,071 crore, while net profit dropped 69% year-on-year to ₹443 crore.
• The target for generic semaglutide pen supply in FY27 was revised down to 6 million to 7 million units from the initial target of 12 million units.

What's Changed

• Semaglutide supply target was cut to 6 million to 7 million pens from the earlier estimate of 12 million pens for FY27.
• A one-time ₹240 crore inventory provision severely hit Q1 FY27 margins, reducing reported EBITDA to ₹1,009 crore with a 12.5% margin.

Key Takeaways

• Dr. Reddy's voluntarily halted semaglutide injectable shipments due to an out-of-specification degradation impurity discovered during scale-up.
• The remediation process is on track for completion by mid-September 2026, enabling API supplies to CDMO partner OneSource by October 2026.
• Commercial distribution of finished products is set to restart between late October and early November 2026, focusing on G3/G7 markets and India.
• The base business (excluding lenalidomide) showed strong growth, and the company maintains its guidance of double-digit revenue growth and 20% operating margin.

SAHI Perspective

The near-term setback in Dr. Reddy's semaglutide pipeline is a quality-control hurdle rather than a systemic failure. Since no commercial batches had to be recalled from patients and regulatory approvals remain valid, the impact is primarily financial (a ₹240 crore write-down) and operational (a 3-to-4 month launch delay in emerging markets like Brazil and Mexico). Sourcing and manufacturing alignment with OneSource Specialty Pharma is crucial to execute the revised 6 million to 7 million pen delivery in H2 FY27.

Market Implications

The temporary supply freeze has given competitors an opening, causing short-term pressure on Dr. Reddy's stock. However, a rapid resolution by November 2026 will allow the company to protect its first-mover generic advantage in Canada and expand in the lucrative GLP-1 receptor agonist space.

Trading Signals

Market Bias: Neutral

While the Q1 FY27 earnings were severely dragged down by the ₹240 crore semaglutide provision, the structured remediation timeline to resume supplies by November 2026 acts as a strong medium-term stabilizer.

Overweight: Pharmaceuticals - GLP-1 space

Underweight: US Generics exporters facing high pricing pressure

Trigger Factors:

• Resolution of the semaglutide API quality issue by the third week of September 2026.
• Resumption of commercial manufacturing at CDMO partner OneSource in early October 2026.
• Relaunch of Obeda injectables in India and generic semaglutide in Canada by November 2026.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global market for GLP-1 receptor agonists is expanding exponentially, led by Novo Nordisk's Ozempic. Indian generic drugmakers are rushing to secure early-mover advantages as patents expire. Dr. Reddy's was the first to launch generic semaglutide injection in Canada and under the brand Obeda in India, highlighting the high stakes of resolving manufacturing and formulation challenges quickly.

Key Risks to Watch

• Delays in the API quality remediation process beyond September 2026.
• Potential loss of market share in Canada and India to competing generic manufacturers if the supply gap widens.
• Regulatory scrutiny or stricter quality-control audits at the API or CDMO manufacturing facilities.

Recent Developments

Dr. Reddy's launched generic semaglutide injection in Canada in May 2026 following Health Canada approval. It also launched its oral semaglutide product under the brand Obeda in India in May 2026, which remains unaffected by the injectable API supply halt.

Closing Insight

Dr. Reddy's management's prompt disclosure and clear remediation roadmap demonstrate strong governance. If the company successfully resumes shipments by November 2026, the Q1 financial dip will likely be viewed as a temporary bottleneck in a highly promising long-term therapeutic segment.

High Performance Trading with SAHI.